Is this you? Create Your Porfile
Avatar

Schoenafinger Karl

Aventis Pharma

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Schoenafinger Karl is active.

Explore More

Publication

Featured researches published by Schoenafinger Karl.

Archive | 1998

New substituted 4-amino-2-aryl-pyrimidines, are soluble guanylate cyclase activators useful e.g. for treating atherosclerosis, hypertension, angina pectoris, thrombosis, asthma or diabetes

Schindler Ursula; Schoenafinger Karl; Strobel Hartmut

Archive | 1994

Verwendung von 1.2.5-Oxadiazol-2-oxiden zur Behandlung erektiler Dysfunktionen

Schoenafinger Karl; Brendel Joachim; Stief Christian

Archive | 1993

Use of sydnonimines to treat erectile dysfunction

Schoenafinger Karl; Kujath Eckard; Stief Christian

Archive | 2000

New 4-amino-2-aryl-cyclopentapyrimidine derivatives are activators of soluble guanylate cyclase, useful for treating or preventing e.g. thrombosis and restenosis

Schindler Ursula; Schoenafinger Karl; Strobel Hartmut

Archive | 1999

Sulfonylamino-carbonsäure-n-arylamide als guanylatcyclase-aktivatoren

Schindler Ursula; Schoenafinger Karl; Strobel Hartmut

Archive | 2007

derivados de 4-benzimidazol-2-ilpiridazin-3-ona

Hoelder Swen; Schoenafinger Karl; Will David William; Matter Hans; Mueller Guenther; Combeau Cecile; Delaisi Christine; Steinmetz Anke; Sassoon Ingrid

Archive | 2003

N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung

Schoenafinger Karl; Defossa Elisabeth; Kadereit Dieter; Roedern Erich Von; Klabunde Thomas; Burger Hans-Joerg; Herling Andreas; Wendt Karl-Ulrich

Archive | 2001

New 5-alkoxy-3-phenyl-3H-1,3,4-oxadiazol-2-one derivatives, are hormone-sensitive lipase inhibitors useful for treating metabolic disorders such as non-insulin dependent diabetes mellitus

Schoenafinger Karl; Petry Stefan; Mueller Guenter; Baringhaus Karl-Heinz

Archive | 2013

Indanilaminas aciladas y su uso como productos farmacéuticos

Strobel Hartmut; Wohlfart Paulus; Safarova Alena; Walser Armin; Suzuki Teri; Dharanipragada Ramalinga M; Schoenafinger Karl

Archive | 2013

DERIVADOS DE SULFONIL-FENIL-2H-(1,2,4)OXADIAZOL-5-ONAS, PROCESSOS PARA SUA PREPARAÇÃO E SEU USO COMO FARMACÊUTICOS

Keil Stefanie; Urmann Matthias; Schoenafinger Karl; Wendler Wolfgang; Glien Maike; Schaefer Hans-Ludwig; Falk Eugen

Explore More

Collaboration

Dive into the Schoenafinger Karl's collaboration.

Top Co-Authors
Avatar

Defossa Elisabeth

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Kadereit Dieter

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Klabunde Thomas

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Herling Andreas

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Schindler Ursula

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Burger Hans-Joerg

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Mueller Guenter

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Petry Stefan

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Wendt Karl-Ulrich

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Strobel Hartmut

Aventis Pharma

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge